StreetInsider.com News Articles

Chardan Starts Inhibikase Therapeutics Inc (IKT) at Neutral

Tue, 13 Oct 2026 02:59:05 -0400

Chardan analyst Andreas Argyrides initiates coverage on Inhibikase Therapeutics Inc (NASDAQ: IKT) with a Neutral rating and a price target of $1.50.

The analyst comments: “We initiate coverage of Inhibikase Therapeutics (IKT) with a Neutral rating and $1.50 price target. IKT-001 is a once-daily oral prodrug of imatinib whose active metabolite inhibits PDGFRα/β, c KIT and ABL kinases implicated in pulmonary vascular remodeling in pulmonary arterial hypertension (PAH). Imatinib’s efficacy in PAH is well established, but IKT-001 has no human PAH data-to-date. Its thesis rests on bioequivalence to oral imatinib and the premise that a prodrug can improve tolerability without diluting

Chardan Starts Inhibikase Therapeutics Inc (IKT) at Neutral

Tue, 13 Oct 2026 02:59:05 -0400

Chardan analyst Andreas Argyrides initiates coverage on Inhibikase Therapeutics Inc (NASDAQ: IKT) with a Neutral rating and a price target of $1.50.

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:01:00 -0400

WILMINGTON, Del., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 128,000 shares of the Company’s common stock to two newly-hired non-executive employees under the Company’s 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of September 30, 2026 (the “Effective Date”). The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:01:00 -0400

Form 8-K Inhibikase Therapeutics, For: Aug 21

Wed, 26 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260826/26981622.html

Form 8-K Inhibikase Therapeutics, For: Aug 21

Wed, 26 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260826/26981622.html

Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26932841.html

Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26932841.html

Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26932114.html

Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Nantahala Capital Management, LLC

Fri, 14 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26932114.html

Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Sands Capital Life Sciences Pulse Fund II, L.P.

Thu, 13 Aug 2026 11:49:00 -0400

si-local-file:///var/storage/secattach/20260813/26918797.html

Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Sands Capital Life Sciences Pulse Fund II, L.P.

Thu, 13 Aug 2026 11:49:00 -0400

si-local-file:///var/storage/secattach/20260813/26918797.html

Inhibikase Therapeutics (IKT) Reports In-Line Q2 EPS

Tue, 11 Aug 2026 17:05:45 -0400

Inhibikase Therapeutics (NASDAQ: IKT) reported Q2 EPS of ($0.11), in-line with the analyst estimate of ($0.11).

For earnings history and earnings-related data on Inhibikase Therapeutics (IKT) click here.

Form S-8 Inhibikase Therapeutics,

Tue, 11 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260811/26906252.html

Form S-8 Inhibikase Therapeutics,

Tue, 11 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260811/26906252.html

Form 10-Q Inhibikase Therapeutics, For: Jun 30

Tue, 11 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260811/26906041.html

Form 10-Q Inhibikase Therapeutics, For: Jun 30

Tue, 11 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260811/26906041.html

Form 8-K Inhibikase Therapeutics, For: Aug 11

Tue, 11 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260811/26905736.html

Form 8-K Inhibikase Therapeutics, For: Aug 11

Tue, 11 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260811/26905736.html

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

Tue, 11 Aug 2026 16:01:00 -0400

WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2026, and highlighted recent developments.

“During our second quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study with 26 country regulatory approvals together with the recent initiation of 43 clinical sites across a range of countries,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “Also, during the quarter,

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

Tue, 11 Aug 2026 16:01:00 -0400

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

Tue, 11 Aug 2026 16:01:00 -0400

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

Tue, 11 Aug 2026 16:01:00 -0400

Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 31 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260731/26851255.html

Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 31 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260731/26851255.html